Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $97.6 million.

  • Vanda Pharmaceuticals' Operating Expenses rose 5373.91% to $97.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $367.3 million, marking a year-over-year increase of 5339.34%. This contributed to the annual value of $367.3 million for FY2025, which is 5339.34% up from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Operating Expenses stood at $97.6 million for Q4 2025, which was up 5373.91% from $87.5 million recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Operating Expenses registered a high of $97.6 million during Q4 2025, and its lowest value of $44.8 million during Q3 2023.
  • For the 5-year period, Vanda Pharmaceuticals' Operating Expenses averaged around $64.4 million, with its median value being $59.9 million (2021).
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Operating Expenses tumbled by 2703.14% in 2023, and later soared by 6062.4% in 2025.
  • Vanda Pharmaceuticals' Operating Expenses (Quarter) stood at $59.4 million in 2021, then fell by 2.58% to $57.9 million in 2022, then dropped by 9.49% to $52.4 million in 2023, then increased by 21.2% to $63.5 million in 2024, then soared by 53.74% to $97.6 million in 2025.
  • Its Operating Expenses was $97.6 million in Q4 2025, compared to $87.5 million in Q3 2025 and $91.1 million in Q2 2025.